A highly recurrent novel missense mutation in CD28 among angioimmunoblastic T-cell lymphoma patients

Haematologica

Volumn 100, Issue 12, 2015, Pages e505-e507

  Lee, Seung Ho ^a   Kim, Ji Sun ^a   Kim, Jaesang ^b   Kim, Seok Jin ^c,d   Kim, Won Seog ^c,d   Lee, Sanghyuk ^b   Ko, Young Hyeh ^c,d   Yoo, Hae Yong ^a,c  

^a Sungkyunkwan University   (South Korea)

^b Ewha Womans University   (South Korea)

^c Samsung Medical Center   (South Korea)

^d Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Angioimmunoblastic T cell lymphoma; CD28; Somatic mutation

Indexed keywords

CD28 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 2; PROTEIN KINASE B; TUMOR PROTEIN;

ANGIOIMMUNOBLASTIC T CELL LYMPHOMA; CELL FUNCTION; CELL PROLIFERATION; HUMAN; LETTER; MISSENSE MUTATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; AMINO ACID SUBSTITUTION; FEMALE; GENETICS; MALE; T CELL LYMPHOMA;

AMINO ACID SUBSTITUTION; ANTIGENS, CD28; FEMALE; HUMANS; LYMPHOMA, T-CELL; MALE; MUTATION, MISSENSE; NEOPLASM PROTEINS;

EID: 84948966037     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2015.133074     Document Type: Letter

References (15)

1. Vose J, Armitage J, Weisenburger D, International TCLP. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124-4130.
2. Cairns RA, Iqbal J, Lemonnier F, et al. IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood. 2012;119(8):1901-1903.
3. Couronne L, Bastard C, Bernard OA. TET2 and DNMT3A mutations in human T-cell lymphoma. N Engl J Med. 2012;366(1):95-96.
4. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol. 1996;14:233-258.
5. Yoo HY, Sung MK, Lee SH, et al. A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma. Nat Genet. 2014;46(4):371-375.
6. Rohr J, Guo S, Hu D, et al. CD28 mutations in peripheral T-cell lymphomagenesis and progression. Blood. 2014; 124(21):1681 abstract
7. Pages F, Ragueneau M, Rottapel R, et al. Binding of phosphatidylinositol-3-OH kinase to CD28 is required for T-cell signalling. Nature. 1994;369(6478):327-329.
8. Schneider H, Cai YC, Prasad KV, et al. T cell antigen CD28 binds to the GRB-2/SOS complex, regulators of p21ras. Eur J Immunol. 1995;25(4):1044-1050.
9. Ellis JH, Ashman C, Burden MN, et al. GRID: a novel Grb-2-related adapter protein that interacts with the activated T cell costimulatory receptor CD28. J Immunol. 2000;164(11):5805-5814.
10. Watanabe R, Harada Y, Takeda K, et al. Grb2 and Gads exhibit different interactions with CD28 and play distinct roles in CD28-mediated costimulation. J Immunol. 2006;177(2):1085-1091.
11. King PD, Sadra A, Teng JM, et al. Analysis of CD28 cytoplasmic tail tyrosine residues as regulators and substrates for the protein tyrosine kinases, EMT and LCK. J Immunol. 1997;158(2):580-590.
12. Prasad KV, Cai YC, Raab M, et al. T-cell antigen CD28 interacts with the lipid kinase phosphatidylinositol 3-kinase by a cytoplasmic Tyr(P)-Met-Xaa-Met motif. Proc Natl Acad Sci USA. 1994; 91(7):2834-2838.
13. Stein PH, Fraser JD, Weiss A. The cytoplasmic domain of CD28 is both necessary and sufficient for costimulation of interleukin-2 secretion and association with phosphatidylinositol 3'-kinase. Mol Cell Biol. 1994;14(5):3392-3402.
14. Okkenhaug K, Wu L, Garza KM, et al. A point mutation in CD28 distinguishes proliferative signals from survival signals. Nat Immunol. 2001;2(4):325-332.
15. Boomer JS, Deppong CM, Shah DD, et al. Cutting edge: a doublemutant knockin of the CD28 YMNM and PYAP motifs reveals a critical role for the YMNM motif in regulation of T cell proliferation and Bcl-xL expression. J Immunol. 2014;192(8):3465-3469.